Literature DB >> 32099471

The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy.

Chao Chen1, Hao Dong1, Chunhui Shou1, Xiaoxiao Shi1, Qing Zhang1, Xiaosun Liu1, Kankai Zhu1, Baishu Zhong2, Jiren Yu1.   

Abstract

PURPOSE: To investigate the feasibility and utility of computer tomography (CT) volumetry in evaluating the tumor response to neoadjuvant chemotherapy (NAC) in advanced gastric cancer (AGC) patients. PATIENTS AND METHODS: One hundred and seventeen Patients with AGC who received NAC followed by R0 resection between January 2006 and December 2012 were included. Tumor volumes were quantified using OsiriX software. The volume reduction rate (VRR) was calculated as follows: VRR = [(pre-chemotherapy total volume) - (post-chemotherapy total volume)]/(pre-chemotherapy total volume) × 100%. The optimal cut-off VRR for differentiating favorable from unfavorable prognosis was determined by receiver operating characteristic (ROC) analysis. Overall survival was calculated using Kaplan-Meier analysis and values were compared using the Log-rank test. Multivariate analysis was determined by the Cox proportional regression model.
RESULTS: The optimal cut-off VRR was 31.95% according to ROC analysis, with a sensitivity of 70.4% and a specificity of 71.7%. Based on the cut-off VRR, patients were divided into the VRR-High (VRR ≥ 31.95%, n = 63) and VRR-Low (VRR < 31.95%, n = 54) groups. The VRR-Low group exhibited a worse prognosis than that of the VRR-High group (HR, 2.85; 95% CI, 1.69-4.82, P < 0.001), with 3-year survival rates of 40.7% and 79.4%, and 5-year survival rates of 31.5% and 63.5%, respectively.
CONCLUSION: CT volumetry is a feasible and reliable method for assessing the tumor response to NAC in patients with AGC.
© 2020 Chen et al.

Entities:  

Keywords:  advanced gastric cancer; computed tomography volumetry; neoadjuvant chemotherapy

Year:  2020        PMID: 32099471      PMCID: PMC7006857          DOI: 10.2147/CMAR.S231636

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  27 in total

1.  Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).

Authors:  Yukinori Kurokawa; Taro Shibata; Mitsuru Sasako; Takeshi Sano; Akira Tsuburaya; Yoshiaki Iwasaki; Haruhiko Fukuda
Journal:  Gastric Cancer       Date:  2013-09-03       Impact factor: 7.370

2.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

4.  Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study.

Authors:  Jian Xiao; Yuting Tan; Wenyun Li; Jiaying Gong; Zhiyang Zhou; Yan Huang; Jian Zheng; Yanhong Deng; Lei Wang; Junsheng Peng; Donglin Ren; Ping Lan; Jianping Wang
Journal:  Oncol Lett       Date:  2015-04-07       Impact factor: 2.967

5.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  CT volumetry for gastric carcinoma: association with TNM stage.

Authors:  James T P D Hallinan; Sudhakar K Venkatesh; Luke Peter; Andrew Makmur; Wei Peng Yong; Jimmy B Y So
Journal:  Eur Radiol       Date:  2014-07-21       Impact factor: 5.315

Review 8.  The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.

Authors:  Katja Ott; Florian Lordick; Ken Herrmann; Bernd-Joachim Krause; Christoph Schuhmacher; Jörg Rüdiger Siewert
Journal:  Gastric Cancer       Date:  2008-03-29       Impact factor: 7.370

Review 9.  Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response.

Authors:  James Thomas Patrick Decourcy Hallinan; Sudhakar Kundapur Venkatesh
Journal:  Cancer Imaging       Date:  2013-05-30       Impact factor: 3.909

Review 10.  Gastric cancer and imaging biomarkers: Part 1 - a critical review of DW-MRI and CE-MDCT findings.

Authors:  Francesco Giganti; Lei Tang; Hideo Baba
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.